Leading the way to safer medication
 Crosscheck  Recommender

Arsenic trioxide

Also known as: Arsenic Sesquioxide Arsenic Oxidearsenous Trioxide

Therapeutic Indications

Arsenic trioxide is indicated for:

Acute promyelocytic leukaemia

Irrespective of gender only Adults (18 years old or older)

Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:

  • Νewly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤10 × 103/µl) in combination with all-trans-retinoic acid (ATRA)
  • Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 0.15 mg/kg once daily

Contraindications

Active ingredient Arsenic trioxide is contraindicated in the following cases: